Epigenetics refers to heritable changes in phenotype without alterations to the genotype. Epigenetic changes involve two main mechanisms: DNA methylation and histone modification. Methylation of DNA at cytosine bases is the best-studied epigenetic process to date. CpG methylation states are thought to be maintained throughout cell divisions. However, loss of DNA methylation or DNA demethylation has been observed in specific stages of mammalian development. Such prominent examples of developmental DNA demethylation processes occur in developing primordial germ cells and in preimplantation embryos. However, little is known about DNA methylation changes of other tissues in mammalian development. Therefore, the first aim of this PhD study was to investigate changing nuclear distributions and levels of DNA methylation during development in order to discover dynamic variations amongst developing mouse tissues. In addition, a transgenic MBD-GFP mouse was employed to visualise DNA methylation in tissues. Several hypothetical mechanisms for the enzymatic removal of 5mC have been proposed. One of the proposed candidates is Tet-mediated successive oxidation of 5mC to generate 5hmC, 5fC and 5caC. 5hmC has therefore been considered as a transient intermediate in an active cytosine demethylation pathway. Nevertheless, some studies suggest that 5hmC may also function as an epigenetic modification in its own right. Thus, the second aim of this study was to address the research question of how and where 5hmC originates during development. In order to be able to identify tissues undergoing dynamic nuclear changes in DNA methylation and hydroxymethylation states during early mouse development, new working protocols for immunodetection of 5mC and 5hmC on tissue cryosections were required. The protocol optimisation for 5mC immunodetection is discussed in greater detail in Chapter 3. It was found that DNA methylation immunostaining of cryosections required heat-mediated DNA denaturation, which was partly compatible with protein immunostaining. Next, Chapter 4 focuses on identifying tissues undergoing dynamic changes in 5mC and 5hmC patterns during development from E9.5 to E14.5 mouse embryonic stages, using optimised immunohistochemistry protocols. These protocols revealed interesting dynamic observations of 5mC and 5hmC in the developing cerebral neocortex, surface ectoderm, liver, red blood cells, diaphragm and heart. These findings suggested that dynamic changes of 5mC and 5hmC during neocortical and compact myocardial development were in good agreement with a model where the formation of 5hmC may correlate with the loss of old 5mC, but the observations were also consistent with an involvement of de novo methylation in the generation of 5hmC. In other developing tissues, including surface ectoderm, liver, red blood cells, diaphragm and cardiac trabeculae, dynamic changes in 5mC and 5hmC levels were in line with a model where the 5hmC may act as a new epigenetic mark that functions independently. The optimised protocol also confirmed DNA demethylation of the germ cells at E12.5. The presence of three Tet family enzymes (Tet1, Tet2, Tet3) and de novo methyltransferase DNMT3A in mouse E12.5 tissues is reported in the second part of Chapter 4. It was found that Tet1, Tet2, Tet3 and Dnmt3a were present at detectable levels in neocortex, liver, diaphragm and heart. Contrastingly, no apparent signals for Tet1, Tet2, Tet3 and Dnmt3a were observed in red blood cells. This result was expected due to the very low levels of 5hmC staining in E12.5 red blood cells. The third aim of the present study was to investigate the existence of crosstalk between various epigenetic mechanisms. Thus, Chapter 5 focuses on exploring the relationship between 5mC and repressive histone marks, H3K9me3 and H3K27me3. Histone methylation dynamics at H3K9 and H3K27 were observed during mouse fetal development in neocortex and heart. The overall distribution patterns of H3K9me3 and H3K27me3 demonstrated strong association with developmental changes in 5mC, suggesting that these three repressive epigenetic marks work in concert to establish a silenced state of heterochromatin. Chapter 6, on the other hand, focuses on visualising DNA methylation in tissues using mouse transgenic tools. It was found that brain, liver, heart and neural tube expressed high levels of GFP. But no apparent developmental dynamics of GFP was observed. In conclusion, this study will contribute scientific understanding of dynamic DNA methylation and nuclear heterochromatin organisation during mammalian development, and its role in the specification and maintenance of cell lineages forming tissues and organs. This knowledge will provide insight into current barriers to cell fate reprogramming, which will be of benefit to cell regenerative biomedical technologies.

Les mutations de TET2, IDH2 et DNMT3A, 3 gènes impliqués dans la régulation de la méthylation de l'ADN, sont fréquentes dans les lymphomes T périphériques (PTCL), mais leurs conséquences sont mal connues. Nous avons montré que les mutations d'IDH2 dans les lymphomes angioimmunoblastiques (AITL) sont restreintes aux cellules T tumorales et que l'enzyme mutée, exprimée dans des lymphocytes T, produit bien l'oncometabolite D-2 hydroxyglutarate (D-2HG). Utilisant des modèles de souris transgéniques, nous avons montré que, dans un lymphocyte T, seule la mutation IDH2R172K produit suffisamment de D-2HG pour inhiber les protéines TET et altérer la différentiation lymphoïde. Ceci peut expliquer qu'IDH2R172 soit la seule mutation d'IDH retrouvée dans les AITL. Les mutations d'IDH2 inhibant les protéines TET, ce qui conduit à une baisse de la 5 hydroxyméthylcytosine (5hmC), nous avons évalué le niveau de 5hmC dans des PTCL mutés ou non pour TET2, IDH2 et/ou DNMT3A. Par rapport aux lymphocytes T normaux, nous avons vu une perte de 5hmC dans les cellules tumorales des PTCL, qui de façon intéressante était présente dans toutes les entités étudiées, quel que soit le statut mutationnel, à l'exception des lymphomes T hépatospléniques. Dans une démarche plus transversale, nous avons montré que la fréquence élevée de mutations de TET2, IDH2 et DNMT3A dans des PTCL présentant des caractéristiques TFH permet d'apporter un argument moléculaire, qui s'ajoute aux similitudes histologiques et phénotypiques pour regrouper ces lymphomes avec les AITL. Enfin, la description de l'efficacité d'un traitement par 5 azacytidine chez une patiente atteinte de AITL mutée pour TET2, suggère que les traitements ciblant l'épigénétique pourraient être efficaces dans ces maladies. / TET2, IDH2 and DNMT3A, 3 genes involved in the regulation of DNA methylation, are frequently mutated in Peripheral T Cell Lymphomas (PTCL). However, the consequences of these mutations are poorly understood. Focusing on IDH2 mutation, we demonstrated that this mutation is restricted to tumor T cells within angioimmunoblastic lymphoma (AITL) tumor tissue. We also demonstrated that, in AITL, IDH2 mutated T cells had the ability to produce D-2 hydroxyglutarate (D-2HG), a metabolite that has oncogenic effect. Using transgenic mouse models, we showed that IDH2R172K was the only IDH mutation that, when expressed in T cells, produced enough D-2HG to inhibit TET proteins and impairing lymphoid differentiation. This likely explains why IDH2R172 is the only IDH mutation found in AITL. As IDH2 mutation results in TET2 inhibition, which impairs 5hmC formation, we assessed the level of 5hmC in AITL, and described 5hmC loss, compared to normal TFH, in all AITL, regardless of the TET2, IDH2 and DNMT3A mutational status. We extended these finding to main nodal and extranodal PTCL entities, showing that 5hmC loss was a general mechanism present in all PTCL, with the exception of hepatosplenic T cell lymphoma. In a translational approach, we saw that the high frequency of TET2, DNMT3A and RHOA mutations in TFH like PTCL suggest a common molecular basis shared with AITL that could argue, in addition to phenotypic and histological similarities, to group these 2 entities into a single category. Finally, we described the first complete remission of a patient with a TET2 mutated AITL with 5 azacytidine, suggesting that hypomethylating agents could be active in PTCL.

La génération de plasmocytes (PC) à longue durée de vie sécrétant des anticorps hautement affins spécifiques de l’antigène, caractéristique de la réponse immune adaptative, est l’étape ultime de la différenciation des lymphocytes B au sein des centres germinatifs des organes lymphoïdes secondaires. La transition d’un lymphocyte B naïf vers un PC est associée au passage d’un programme transciptionnel des gènes de l’identité B vers l’expression des gènes de l’indentité plasmocytaire. Ce travail de thèse s’est concentré sur la caractérisation de cette étape terminale de la différenciation lymphocytaire B humaine tant au niveau transcriptomique qu’épigénétique. A l’aide d’un modèle de différenciation in vitro à partir de lymphocytes B naïfs humains, nous avons identifié les cellules engagées dans ce processus. Ces précurseurs des plasmablates sont notamment caractérisés par une répression de la voie de signalisation de l’IL-4 aboutissant à la perte du marqueur CD23, le récepteur de faible affinité à l’IgE mais aussi à l’apposition de 5hmC, l’hydroxyméthylcytosine, au niveau des gènes de l’identité PC. L’étude de cette marque épigénétique dans un contexte pathologique, le myélome multiple, a fait l’objet du second axe de recherche de notre projet et a révélé le rôle du gène FAM72D dans la prolifération cellulaire. / The generation of long-lived plasma cells (PCs) secreting protective, antigen-specific, high-affinity antibodies as a part of adaptative immunity, is the ultimate step of the terminal differentiation of B cells within germinal centers of secondary lymphoid organs. The transition of a naïve B cell into a PC is associated with the switch from a B cell identity programm to PC identity programm. The focus of this thesis project was to characterise the transcriptomic and épigenetic profile of cells commited to this ultimate step of the B cell differentiation. Thanks to an in vitro model of human naïve B cell differentiation into PCs, we identify cells commited to this process. These plasmablasts founder cells are caracterised by a downregulation of the IL-4 pathway leading to the loss of CD23, the low-affinity receptor for IgE, but also to the hydroxymethylation (5hmC apposition) of PC identity genes. The study of 5hmC in multiple myeloma samples was the subject of the second research axis of our project and revealed the role of FAM72D gene as a marker of cell proliferation.

Deregulation of the epigenome is associated with the initiation and progression of various types of human cancers. Here we investigated the level of 5-hydroxymethylcytosine (5hmC), expression and function of TET1 and TET2, and DNA methylation in parathyroid tumors and small intestinal neuroendocrine tumors (SI-NETs). In Paper I, an undetectable/very low level of 5hmC in parathyroid carcinomas (PCs) compared to parathyroid adenomas with positive staining, suggested that 5hmC may represent a novel biomarker for parathyroid malignancy. Immunohistochemistry revealed that increased tumor weight in adenomas was associated with a more aberrant staining pattern of 5hmC and TET1. A growth regulatory role of TET1 was demonstrated in parathyroid tumor cells. Paper II revealed that the expression of TET2 was also deregulated in PCs, and promoter hypermethylation was detected in PCs when compared to normal parathyroid tissues. 5-aza-2′-deoxycytidine treatment of a primary PC cell culture induced TET2 expression and further supported involvement of promoter hypermethylation in TET2 gene repression. TET2 knockout demonstrated a role for TET2 in cell growth and migration, and as a candidate tumor suppressor gene. In Paper III, variable levels of 5hmC, and aberrant expression of TET1 and TET2 were observed in SI-NETs. We demonstrated a growth regulatory role for TET1, and cytoplasmic expression with absent nuclear localization for TET2 in SI-NETs. In vitro experiments supported the involvement of exportin-1 in TET2 mislocalization, and suggested that KPT-330/selinexor, an orally bioavailable selective inhibitor of exportin-1 and nuclear export, with anti-cancer effects, could be further investigated as a therapeutic option in patients with SI-NETs. In Paper IV, DNA methylation was compared between SI-NET primary tumors and metastases by reduced representation bisulfite sequencing. Three differentially methylated regions (DMR) on chromosome 18 were detected and chosen for further analyses. The PTPRM gene, at 18p11, displayed low expression in SI-NETs with high levels of methylation in the presumed CpG island shores, and in the DMR rather than the promoter region or exon 1/intron 1 boundary. PTPRM overexpression resulted in inhibition of cell growth, proliferation, and induction of apoptosis in SI-NET cells, suggesting a role for PTPRM as an epigenetically deregulated candidate tumor suppressor gene in SI-NETs.

During the process of spermatogenesis, histones are replaced by protamines, basic proteins enabling transmission of DNA to the oocyte during fertilization. In mouse sperm, there is only 1% of remaining histones whose N-terminal tails contain post-translationally modified residues. In this study, I was interested in contribution of paternal histone H4 acetylated on lysine K12 residues (H4K12ac) that is present in mature sperm head in remaining nucleosomes. Physiologically, H4K12ac has an important role in transcription factor accumulation and in regulation of gene expression. The presence and abundance of H4K12ac modification in various pronuclei stages of 1-cell embryo and parthenotes were assessed by imunnoflourescent detection with utilization of anti-H4K12ac antibody. Altogether, the paternal pronucleus exhibits a strong acetylation signal on H4K12 since its formation, while in the maternal one, there is a slow continual increase of H4K12ac getting on the same level as paternal pronucleus till the pronuclei fusion. Simultaneously DNA methylation status in both pronuclei was detected. In paternal pronucleus there is a continual decrease in the DNA methylation detectable as a decrease of 5mC and an increase of 5hmC signal. Meanwhile, the maternal pronucleus stays widely methylated. DNA...

I proposed the study of two distinct aspects of Ten-Eleven Translocation 2 (TET2) protein for understanding specific functions in different body systems. In Part I, I characterized the molecular mechanisms of Tet2 in the hematological system. As the second member of Ten-Eleven Translocation protein family, TET2 is frequently mutated in leukemic patients. Previous studies have shown that the TET2 mutations frequently occur in 20% myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN), 10% T-cell lymphoma leukemia and 2% B-cell lymphoma leukemia. Genetic mouse models also display distinct phenotypes of various types of hematological malignancies. I performed 5-hydroxymethylcytosine (5hmC) chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq) of hematopoietic stem/progenitor cells to determine whether the deletion of Tet2 can affect the abundance of 5hmC at myeloid, T-cell and B-cell specific gene transcription start sites, which ultimately result in various hematological malignancies. Subsequent Exome sequencing (Exome-Seq) showed that disease-specific genes are mutated in different types of tumors, which suggests that TET2 may protect the genome from being mutated. The direct interaction between TET2 and Mutator S Homolog 6 (MSH6) protein suggests TET2 is involved in DNA mismatch repair. Finally, in vivo mismatch repair studies show that the loss of Tet2 causes a mutator phenotype. Taken together, my data indicate that TET2 binds to MSH6 to protect genome integrity. In Part II, I intended to better understand the role of Tet2 in the nervous system. 5-hydroxymethylcytosine regulates epigenetic modification during neurodevelopment and aging. Thus, Tet2 may play a critical role in regulating adult neurogenesis. To examine the physiological significance of Tet2 in the nervous system, I first showed that the deletion of Tet2 reduces the 5hmC levels in neural stem cells. Mice lacking Tet2 show abnormal hippocampal neurogenesis along with 5hmC alternations at different gene promoters and corresponding gene expression downregulation. Through the luciferase reporter assay, two neural factors Neurogenic differentiation 1 (NeuroD1) and Glial fibrillary acidic protein (Gfap) were down-regulated in Tet2 knockout cells. My results suggest that Tet2 regulates neural stem/progenitor cell proliferation and differentiation in adult brain.

Les cellules souches hématopoïétiques (CSH) assurent une production constante des cellules sanguines tout au long de la vie, mais sont vulnérables à l’acquisition de mutations pouvant mener à une transformation maligne. Les mutations qui confèrent un avantage de croissance entraîneront une prolifération clonale. L’étude de la clonalité est centrale à la compréhension de ces phénomènes. Historiquement, l’analyse de la clonalité a été possible grâce au principe de l’inactivation du chromosome X (ICX) chez les femmes qui entraîne la création de deux populations cellulaires, celle avec le X-paternel actif et celle avec le X-maternel actif. Une déviation (biais) de la proportion théorique de 1 :1 entre ces deux populations peut supposer une dominance clonale. Nous avons démontré un biais significatif de l’ICX chez les femmes avec l’âge. Ce phénomène peut être expliqué par plusieurs causes dont la sélection hémizygote (un des deux X possède des allèles plus forts que l’autre) et l’acquisition de mutations dans une CSH. Nous posons l’hypothèse que ces deux phénomènes coexistent et peuvent être distingués par une approche génomique. Nous avons recruté une cohorte de 2996 femmes canadiennes-françaises âgées entre 37 et 101 ans composée de 2172 individus issus de 321 familles et de 824 individus non apparentés. Deux tissus biologiques ont été recueillis : le sang périphérique (PMN, monocytes, lymphocytes T, lymphocytes B) et des cellules buccales. Le ratio de l’ICX a été déterminé par la méthode HUMARA, l’analyse de gènes associés à l’hématopoïèse clonale (19 gènes) a été faite par la méthode de séquençage NGS, et la cohorte a été génotypée à 700 625 loci polymorphiques de l’ADN (SNP). Des analyses bioinformatiques ont été - iv - appliquées pour étudier la contribution génétique au biais de l’ICX. Nous démontrons que : (i) le biais de l’ICX est plus prévalent dans les cellules sanguines par rapport aux cellules épithéliales et maximal dans les cellules myéloïdes; (ii) le biais augmente avec l’âge seulement dans les cellules sanguines et que cette influence est plus marquée pour les neutrophiles; (iii) la concordance du biais est très importante pour les différents types cellulaires sanguins, suggérant un mécanisme opérant au niveau de la CSH ; (iv) il y a une composante héréditaire liée au biais de l’ICX; (v) la présence de mutations acquises (TET2, DNMT3A, etc.) explique seulement une partie du biais ; (vi) à l’aide d’analyses par liaison génétique la présence d’une région sur le chromosome X à Xq21 (LOD score 4.9) qui est associée au biais des lymphocytes T et une autre sur le chromosome 1 à 1q21 (LOD score 6) qui est associée au biais des neutrophiles. Nous avons départagé la contribution liée à l’acquisition de mutations somatiques et identifié pour la première fois des régions liées à une prédisposition génétique. Nos travaux se poursuivront d’une part par l’analyse de gènes candidats dans les régions identifiées, et d’autre part nous tenterons d’identifier les cibles génétiques qui confèrent un potentiel de transformation maligne en utilisant une approche basée sur l’analyse du méthylome, de l’hydroxyméthylome et du transcriptome que nous venons de valider. Notre étude démontre la complexité de l’adaptation de l’hématopoïèse au vieillissement et ouvre des portes sur l’identification de facteurs prédisposant aux cancers hématologiques. / Hematopoietic stem cells (HSC) ensure a constant lifelong production of blood cells, but are vulnerable to acquisition of mutations, which may lead to malignant transformation. Mutations that confer a growth advantage will lead to clonal derivation of cells. The study of clonality is central to the understanding of hematopoiesis adaptation to aging. Historically, the first clonality assays were based on the principle of X-chromosome inactivation (XCI) in women. Women are mosaics with half the cells with the paternal X active and the other half with the maternal one. A skewing from the theoretical 1:1 ratio between these two populations of cells could infer clonal derivation of cells. More than 20 years ago, our team demonstrated, through analysis of (XCI) in women, that skewing increases with age. This intriguing phenomenon can be explained by several etiology including hemizygous selection (one of the 2 Xs has stronger alleles) or the acquisition of mutations giving a growth advantage. The first etiology is genetically predetermined and the second, acquired in somatic cells of bone marrow. We hypothesize that these two phenomena coexist and can be distinguished with a genomic approach. To test our hypothesis, we investigated skewing in a cohort of 2996 French-Canadian women aged 37 to 101 comprised of 2172 related individuals from 321 families and 824 unrelated individuals. We analyzed XCI ratios at the HUMARA locus in epithelial cells, neutrophils, T-cells, monocytes, B-lymphocytes. We genotyped the cohort for clonal hematopoiesis and looked for germline heritable components by genome wide association studies and linkage analyses. We document that skewing was more prevalent in blood cells than in epithelial cells, and maximal in myeloid cells. Skewing increases with age only in blood cells. Intra- vi - individual correlation of skewing blood cell types was strongly correlated, suggesting selection influences operating at the HSC. Sibship analyses demonstrated heritability which was strongest when parental origin of skewing was taken into account. Clonal hematopoiesis accounted only for a small proportion of the skewing trait but its importance increased in the very old. Linkage analysis identified a region at Xq21 for skewing occurring in T-cells (LOD score 4.9) suggesting a hemizygous cell selection influence. We also identified a region at 1q21 for skewing in neutrophils (LOD score 6) suggesting a gene-gene interaction with Xlinked genes. We have demonstrated that age-associated skewing is a complex trait caused in part by acquired mutations and genetic predisposition variants. We will pursue our investigation using a candidate gene approach in the two identified regions and will try to identify genetic targets of oncogenic potential by a method based on analysis of the methylome, hydroxymethylome and transcriptome that was have validated in this cohort. This thesis demonstrates the complexity of the adaptation mechanisms of hematopoiesis to aging and set the stage to identification of factors predisposing to hematological cancers.